Marginal zone B cells acquire dendritic cell functions by trogocytosis
Patrick Schriek, Alan C. Ching, Nagaraj S. Moily, Jessica M. Moffat, Lynette Beattie, Thiago M. Steiner, Laine Hosking, Joshua M. Thurman, V. Michael Holers, Satoshi Ishido, Mireille H. Lahoud, Irina Caminschi, William R. Heath, Justine D. Mintern, Jóse A. Villadangos
Abstract
Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocytic acquisition of these molecules from conventional dendritic cells (cDCs). Complement component 3 (C3) binds to murine and human MHC II on cDCs. MZ B cells recognize C3 with complement receptor 2 (CR2) and trogocytose the MHC II-C3 complexes, which become exposed on their cell surface. The ubiquitin ligase MARCH1 limits the number of MHC II-C3 complexes displayed on cDCs to prevent their elimination through excessive trogocytosis. Capture of C3 by MHC II thus enables the transfer of cDC-like properties to MZ B cells.